Among all 330 MTC patients enrolled in the phase 3 EXAM trial, 51.2% were RET mutation-positive (38.2% with the RET M918T mutation), 13.9% were RET mutation-negative, and 4.8% were RAS mutation-positive. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.